Member Info for BuenaVista

@Rorydinho, do you know the difference between Phase 1a and Phase 1b? And are you aware that there is no such thing as Phase 1c, Phase 1d, Phase 1e, etc?

Many many ways for a small pharma company to raise capital and all options will be explored. Avacta is fortunate to have many assets and a cash-generative division.

Basically, these FUDsters don't understand the pharma industry and think Avacta's business model is the same as Wilko's. Basically the FUDsters are 🤡🤡, 🤠🤠 and 💩sters.

Never heard of you. Laughing at you now though.

The biggest nothing has changed is that Arm 2 still doesn't have a complete first cohort FIVE MONTHS after announcing the intention to do it and at least TEN WEEKS and likely much longer since screening began. WHY?

Of course they are working on funding. Doh!

AHS thinks Avacta are going to be buying a Coris every year.😂😂😂

£55

That explains the process but doesn't provide any clue as to when the priority application will be published as we don't know what the priority date was, or will be if not filed yet.

When they say that patients in the Arm 2 cohorts will have FAPhigh cancers, I don't think many connected that with the Dx slide having been pulled when the DX overview was being given last year.

A patentee has one year in which to file patent applications around the rest of the world after the first application (the priority application on the priority date) has been filed. These additional applications would typically be made on the last day before the year was up in order to claim the longest possible patent protection. However public disclosure of the invention by any means at any time during that year would invalidate those additional applications.

I'll let you have my thoughts after a few weeks/months Andershow.

This doesn't use CanSEEK. PNT6555 is a version of PNT2004. The Lu version is in Phase 1, the Ac version still in preclinical.

https://www.pointbiopharma.com/our-products/pipeline

Addendum: and not only "subconsciously assume that everyone knows what they know", but also, when proofreading, gloss over the text reading what they expect to see there rather than the text that is actually there.

☝️ A point that immediately occurred to me after rereading what I had just posted and noting errors I missed when checking before posting...

@DTW, I agree that holding updates would be a bad idea, and would just cause more uncertainty and opportunities for FUD.

For me, the problem lies in the incompleteness and ambiguity in the RNS's that ARE released. I suspect that these are created and proof-read by experts who, due to their complete knowledge of the project, subconsciously assume that everyone knows what they know. If they were to give TX RNS's to a couple of DX people (being scientists somewhat removed from the action) to read over they would soon unearth and point out the omissions, inconsistencies and ambiguities. Such a simple thing to do!

If Myles McNulty is meeting management with a set of questions, that would be an excellent way for Avacta kickstart their blog that they agreed (at when was it? Science Day? AGM?) would be a good communication channel. In fact, I'd say it was vital that Avacta do that. Let AS et al write up the responses and post on the Avacta website for all to read. Kills many birds with one stone.

My thoughts:

The patients don't want to take an experimental treatment ahead of the SoC.

And/or

The clinicians are taking patients for other drug trials.

And/or

The selection criteria are too narrow to find the treatment-naive patients they want and they don't want to fill the cohort with pretreated patients.

And/or

The US healthcare system is a serious roadblock for this type of trial.

And/or

Avacta has totally misjudged the time needed to recruit patients.

The intention to do the fortnightly study was announced FIVE MONTHS AGO. Screening was already ongoing TWO MONTHS AGO. Something is seriously wrong somewhere in this process.

Or they could just be writing the RNS blurb from scratch each time rather than using the time saving method of having standard, agreed and approved texts that can just be slotted in as needed. Wouldn't surprise me given the way this company goes about things.

I'm absolutely convinced the board knows what coming. The question is "What is coming?"

We shouldn't forget that article on 'telltale signs your company is about to be taken over' - top management staff who will have no role in the new organisation leaving for other jobs and the company not doing anything to support a continually falling share price that will make the modest takeover premium seem a bargain to traders and frustrated, demoralised investors alike.

And all the while, the silence from the company is deafening.

Of those are the figures then it could just be another Avacta RNS balls up Patrick.

Working on a first approximation of the mid market price being 95p:

9,515 x 95p = £9,039.25

So 3 employees got £3,000 or some combination of more employees getting less each.

It's the bonus for top management? For a project team? A little for a lot of staff? No big deal.

Also gotta say, not the RNS I was hoping for.

You think AS should RNS that the company is in negotiation with other companies?